MX2022009825A - Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. - Google Patents
Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.Info
- Publication number
- MX2022009825A MX2022009825A MX2022009825A MX2022009825A MX2022009825A MX 2022009825 A MX2022009825 A MX 2022009825A MX 2022009825 A MX2022009825 A MX 2022009825A MX 2022009825 A MX2022009825 A MX 2022009825A MX 2022009825 A MX2022009825 A MX 2022009825A
- Authority
- MX
- Mexico
- Prior art keywords
- cell receptors
- mutation
- restricted
- hla class
- tcrs
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 230000035772 mutation Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
Se describen receptores de células T aislados o purificados (TCR), donde los TCR tienen especificidad antigénica por una secuencia de aminoácidos de RAS humana mutada presentada por una molécula de antígeno leucocitario humano (HLA) de la Clase I. También se proporcionan polipéptidos y proteínas relacionados, así como los ácidos nucleicos, vectores de expresión recombinantes, células anfitrionas, poblaciones de células y composiciones farmacéuticas relacionados. También se describen métodos de detección de la presencia de cáncer en un animal y métodos de tratamiento o prevención del cáncer en un animal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976655P | 2020-02-14 | 2020-02-14 | |
| US202063060340P | 2020-08-03 | 2020-08-03 | |
| PCT/US2021/017852 WO2021163477A1 (en) | 2020-02-14 | 2021-02-12 | Hla class i-restricted t cell receptors against ras with g12v mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009825A true MX2022009825A (es) | 2022-10-13 |
Family
ID=74860482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009825A MX2022009825A (es) | 2020-02-14 | 2021-02-12 | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230082787A1 (es) |
| EP (1) | EP4103598A1 (es) |
| JP (1) | JP2023526149A (es) |
| KR (1) | KR20220143875A (es) |
| CN (1) | CN115315441A (es) |
| AU (1) | AU2021220957A1 (es) |
| BR (1) | BR112022015897A2 (es) |
| CA (1) | CA3167382A1 (es) |
| GB (1) | GB2610311A (es) |
| MX (1) | MX2022009825A (es) |
| TW (1) | TW202140535A (es) |
| WO (1) | WO2021163477A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| JP2024518378A (ja) | 2021-05-05 | 2024-05-01 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｐｒａｍｅに特異的に結合する抗原結合タンパク質 |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| WO2023232785A1 (en) * | 2022-05-30 | 2023-12-07 | Hs Diagnomics Gmbh | Common tumor-specific t cell receptors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1545204B1 (en) | 2002-09-06 | 2016-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| US20170319638A1 (en) * | 2016-05-06 | 2017-11-09 | Virttu Biologics Limited | Treatment of cancer |
| US11466071B2 (en) * | 2017-12-04 | 2022-10-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class I-restricted t cell receptors against mutated RAS |
| EP3731861A1 (en) * | 2017-12-29 | 2020-11-04 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | T cell receptors for tumor specific proteasome splice variants and uses thereof |
-
2021
- 2021-02-12 TW TW110105193A patent/TW202140535A/zh unknown
- 2021-02-12 EP EP21710740.8A patent/EP4103598A1/en active Pending
- 2021-02-12 US US17/799,193 patent/US20230082787A1/en active Pending
- 2021-02-12 CA CA3167382A patent/CA3167382A1/en active Pending
- 2021-02-12 CN CN202180014281.4A patent/CN115315441A/zh active Pending
- 2021-02-12 KR KR1020227031589A patent/KR20220143875A/ko unknown
- 2021-02-12 JP JP2022549088A patent/JP2023526149A/ja active Pending
- 2021-02-12 AU AU2021220957A patent/AU2021220957A1/en active Pending
- 2021-02-12 GB GB2211757.6A patent/GB2610311A/en active Pending
- 2021-02-12 WO PCT/US2021/017852 patent/WO2021163477A1/en unknown
- 2021-02-12 BR BR112022015897A patent/BR112022015897A2/pt unknown
- 2021-02-12 MX MX2022009825A patent/MX2022009825A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021163477A8 (en) | 2022-09-29 |
| BR112022015897A2 (pt) | 2022-10-18 |
| AU2021220957A1 (en) | 2022-09-01 |
| EP4103598A1 (en) | 2022-12-21 |
| CA3167382A1 (en) | 2021-08-19 |
| JP2023526149A (ja) | 2023-06-21 |
| KR20220143875A (ko) | 2022-10-25 |
| CN115315441A (zh) | 2022-11-08 |
| WO2021163477A1 (en) | 2021-08-19 |
| US20230082787A1 (en) | 2023-03-16 |
| GB202211757D0 (en) | 2022-09-28 |
| TW202140535A (zh) | 2021-11-01 |
| GB2610311A (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
| MX2022009825A (es) | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. | |
| MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
| US20220148681A1 (en) | Neoantigen identification using hotspots | |
| MX2021015877A (es) | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. | |
| MX2022009654A (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación g12d. | |
| AU2024202903A1 (en) | Neoantigen identification, manufacture, and use | |
| US20220154281A1 (en) | Identification of neoantigens with mhc class ii model | |
| MX2020003117A (es) | Receptores de celulas t restringidas a hla de clase ii contra ras mutado. | |
| CR20200170A (es) | Receptores de células t que reconocen p53 mutado | |
| AU2018328220A1 (en) | Neoantigen identification for T-cell therapy | |
| CA3066635A1 (en) | Neoantigen identification, manufacture, and use | |
| CN111868080A (zh) | 利用泛等位基因模型进行的新抗原鉴别 | |
| EP3045468B1 (en) | Novel peptides and their use in diagnosis and treatment | |
| SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
| MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
| JP2018519243A5 (es) | ||
| CL2023000426A1 (es) | Neoantígenos ras y usos de los mismos | |
| WO2019036043A2 (en) | METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER | |
| WO2021262829A3 (en) | Hla class i-restricted t cell receptors against cd20 | |
| BR112013013158B1 (pt) | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso | |
| KR102182555B1 (ko) | T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼 | |
| WO2022051449A3 (en) | T cell receptors recognizing r273c or y220c mutations in p53 | |
| US20230197192A1 (en) | Selecting neoantigens for personalized cancer vaccine | |
| De Groot | Immunoinformatic analysis of Chinese Hamster Ovary (CHO) protein contaminants in therapeutic protein formulations |